Onco-Summaries: Daily Oncology Updates at a Glance

29/08/2025

BeOne reported positive topline results for sonrotoclax in R/R MCL (Ref)

BeOne Medicines' Phase 1/2 BGB-11417-201 trial of sonrotoclax (BCL2 inhibitor) met its primary endpoint of ORR in adult patients with relapsed/refractory mantle cell lymphoma following treatment with a BTK inhibitor and anti-CD20 therapy.

• Promising results were also observed across several secondary efficacy endpoints, including CR, DOR and PFS

• The safety profile was generally well-tolerated, and the toxicities were manageable

• BeOne plans to present the full data at an upcoming medical meeting